NAMHC Minutes of the 267th Meeting
June 7 and June 8, 2022
Department of Health and Human Services
Public Health Service
National Institutes of Health
National Advisory Mental Health Council
Introduction
The National Advisory Mental Health Council (NAMHC) held its 267th meeting at 12:30 pm, June 7, 2022, via a virtual videocast. In accordance with Public Law 92-463, the session was open to the public until approximately 4:45 pm. Joshua Gordon, M.D., Ph.D., Director of the National Institute of Mental Health (NIMH), presided as Chair.
Chairperson
Joshua Gordon, M.D., Ph.D.
Executive Secretary
Tracy Waldeck, Ph.D.
Council/Ad Hoc Members Present
- Edwin (Ted) Abel, III, Ph.D.
- Laura Almasy, Ph.D.
- Marjorie Baldwin, Ph.D.
- Pamela Collins, M.D., M.P.H.
- David Goldstein, Ph.D.
- Kamilah Jackson, M.D.
- Marguerita Lightfoot, Ph.D.
- Joel Nigg, Ph.D.
- Matthew Nock, Ph.D.
- Patricia Recupero, M.D., J.D.
- Bryan Roth, M.D., Ph.D.
- Joseph Telfair, DrPH, M.P.H.
- Sophia Vinogradov, M.D.
- Hongkui Zeng, Ph.D.
Department of Veteran Affairs (Ex Officio Member)
- Amy Kilbourne, Ph.D., M.P.H.
Liaison Representative
- Anita Everett, M.D. , DFAPA
Others Present at the Open Policy Session (Open Policy Session Roster)
Others present at Closed Grant Review Session (Closed Grant Review Session Roster)
OPEN PORTION OF THE MEETING
- Open Policy Session Call to Order & Opening Remarks, Joshua Gordon, M.D., Ph.D. (NIH Videocast @1:49)
NIMH Director Dr. Joshua Gordon opened the virtual NAMHC meeting and welcomed Council members, NIMH staff, NIH staff, and members from various stakeholder communities. Public comments were collected in written format and distributed to Council members prior to the meeting (See Appendix B).
Following a review of virtual meeting procedures, the Council unanimously passed a motion approving the final Summary Minutes of the February 2022 meeting.
- NIMH Director’s Report, Joshua Gordon, M.D., Ph.D. (NIH Videocast @6:06)
- President’s State of the Union and Unity Agenda
Dr. Gordon talked about the President’s State of the Union Address on March 1, 2022, which outlined the administration’s priorities for the nation. Among these priorities was the announcement of the Unity Agenda , a bipartisan strategy that includes a focus on the nation’s mental health and substance use disorder crises. As presented in the Unity Agenda, the mental health strategy includes three pillars: strengthening system capacity, connecting Americans to care, and supporting Americans by creating healthy environments. The latest version of the Unity Agenda established a federal research action plan spearheaded by the White House Office of Science and Technology Policy (OSTP) to coordinate research efforts across federal agencies, including NIMH.
- Interactions with Congress and the White House
Between February and April 2022, NIMH staff provided briefings to a number of congressional representatives, including Senator Roy Blunt (R-MO) on the Global Child Thrive Act, Representative Ann Kirkpatrick (D-AZ) on the impact of the pandemic on educator mental health, and Representative Don Beyer (D-VA) on suicide prevention research. In March 2022, Dr. Gordon spoke with Friends of NIMH and the Congressional Mental Health Caucus on NIMH advances in early psychosis. In April 2022, Dr. Gordon met with Representative David Trone (D-MD) to provide research updates about COVID-19 and suicide prevention. Later in April 2022, he met with Senate Appropriations Clerks on the research budget request for NIMH. On May 13, 2022, NIMH staff, Nora Volkow, M.D., Director of the National Institute on Drug Abuse, and staff from the Food and Drug Administration met with the Senate Committee on Health, Education, Labor, and Pensions and Senator Chris Murphy’s (D-CT) staff to discuss mental health and substance use disorder legislation. On May 19, 2022, Shelli Avenevoli, Ph.D., NIMH Deputy Director, participated in a virtual discussion with the White House OSTP on adolescent brain development and the effects of stress from the COVID-19 pandemic and social media.
Dr. Gordon also participated in two Congressional hearings. On March 23, 2022, Dr. Gordon testified before the Senate Committee on Health, Education, Labor, and Pensions on strengthening mental health and substance use disorder programs. Other witnesses included Miriam Delphin-Rittmon, Ph.D., Assistant Secretary for Mental Health and Substance Use; Carole Johnson, Administrator, Health Resources and Services Administration; and Dr. Volkow. On May 17, 2022, Dr. Gordon testified before the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies on the proposed Fiscal Year 2023 NIH budget. Other witnesses included Lawrence Tabak, D.D.S., Ph.D., Acting Director of the National Institutes of Health and four NIH Institute Directors.
- Appropriations and Budget Updates
On March 15, 2022, President Biden signed the Consolidated Appropriations Act of 2022 which included a $2.2 billion budget for NIMH, of which $20 million was allocated to expand research on the impact of the COVID-19 pandemic on mental health. The Act also included $45 billion for NIH, of which $1 billion was allocated to launch the Advanced Research Projects Agency for Health (ARPA-H).
- HHS and NIH Updates
On March 2, 2022, Health and Human Services (HHS) Secretary Xavier Becerra announced a National Tour to Strengthen Mental Health to emphasize the need to focus on mental health as the nation moves forward after the pandemic. On March 25, 2022, Secretary Becerra announced the formal establishment of ARPA-H as an independent entity within NIH. Adam Russell, D.Phil., was appointed to serve as Acting Deputy Director of the newly established ARPA-H until President Biden formally appoints a director. In April 2022, Norman Edward “Ned” Sharpless, M.D., stepped down from his role as Director of the National Cancer Institute and Douglas Lowy, M.D., assumed the role of Acting Director until President Biden appoints a new director.
On February 1, 2022, NIH released a request for public comment on the draft NIH-Wide Strategic Plan Framework for Diversity, Inclusion, and Accessibility. On March 17, 2022, NIH issued the new Tribal Consultation Policy which standardizes the process of consultation with American Indian and Alaska Native communities prior to initiating research that includes significant components related to tribal lands or citizens. On February 7, 2022, NIH released its Climate Change and Health Initiative Strategic Framework to guide NIH research on the health impacts of climate change.
From May 11-13, 2022, NIH hosted the Third Annual Helping to End Addiction Long-term (HEAL) Initiative Investigator Meeting . On March 17, 2022, NIH’s All of Us program released its first genomic dataset of nearly 100,000 whole genome sequences, of which approximately 50 percent are from individuals who identify with racial or ethnic groups that have been historically underrepresented in biomedical research. On February 22, 2022, NIH launched the BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS)—a new, transformative project to map neurocircuits in mice, humans, and non-human primates—with three funding announcements . The BRAIN Initiative will host its 8th Annual virtual meeting on June 21 - 22, 2022.
- NIMH News to Know
Dr. Gordon provided an update on the NIMH Strategic Plan. The 2022 update includes expanded information on diversity, equity, and inclusion; information about the NIMH Approach to Mental Health Disparities Research and the NIH Climate Change and Health Initiative; two new interest areas on economic factors related to mental health; and a reorganization of strategies to map interest areas to the developmental pipeline. NIMH also released a 2021 Strategic Plan Progress Report.
Dr. Gordon reviewed the NIMH portfolio, including how the balance between therapeutic development and services research, disease-related basic research, and fundamental basic research has shifted between 2007 and 2020. Between 2010 and 2013 and again in recent years, there was an increased focus on therapeutic development and services. Additionally, there has been a shift from disease-related basic research with medium-term impact to fundamental-related basic research with slightly longer-term impact. Although it can be challenging to compare research portfolios across Institutes, one well-defined metric for comparison is the percentage of clinical trial research within a portfolio. In 2020, NIMH allocated 16 percent of its research budget to clinical trials, which closely mirrors that of NIH overall.
As part of the NIH UNITE Initiative, NIMH developed a Racial and Ethnic Equity Plan (REEP) that is aligned with NIH’s REEP goals: apply a racial and ethnic equity lens to the workforce, structures, and systems; identify and dismantle racial and ethnic disparities in the workforce; enhance diversity in the workforce. In addition to creating a REEP, NIMH is engaged in other activities focused on diversity, equity, inclusion, and accessibility (DEIA). NIMH provided leadership and supervisor training on the role of social and structural determinants of inequity, as well as staff training on strategies to identify microaggressions along with a neurodiverse inclusive workforce. NIMH facilitated group listening sessions with staff, the results of which will be shared with the NIMH Antiracism Task Force and will inform recommendations to improve the NIMH work environment.
The Interagency for Autism Coordinating Committee (IACC) held a virtual meeting on April 13 - 14, 2022. The IACC is currently developing its 2021-2022 IACC Strategic Plan for Autism Research, Services, and Policy and its 2021 Summary of Advances. In addition, the IACC published the 2020 Summary of Advances .
Dr. Gordon announced NIMH’s upcoming 75th anniversary in 2023. NIMH will hold anniversary activities between September 2023 and September 2024 to reflect on past accomplishments, the present state of science, and future directions.
There were a number of changes among NIMH staff. Robert Heinssen, Ph.D., will step down as Director of the NIMH Division of Services and Intervention Research (DSIR) in July and will join the Office of the Director as a special advisor to Dr. Gordon. Joel Sherrill, Ph.D., will serve as Acting Director of DSIR. Joyce Chung, M.D., transitioned from her role as Deputy Clinical Director of the NIMH Intramural Research Program (IRP) and is now serving as the Designated Institutional Officer of the NIH Clinical Center and Executive Director of Graduate Medical Education. Two new staff joined the NIMH IRP: James Bourne, Ph.D., as Chief of the Section on Cellular and Cognitive Development and Angela Langdon, Ph.D., as Chief of the Unit on Neural Computations in Learning. Two members of NIH staff were honored with awards. Sarah H. Lisanby, M.D., Director of the NIMH Division of Translational Research (DTR), was recently inducted as a Distinguished Life Fellow of the American Psychiatric Association. Victoria Arango, Ph.D., Program Officer in DTR, was recently elected President of the Society of Biological Psychiatry.
- Science Highlights
Dr. Gordon shared five science highlights. The first two studies focused on genetics and the biological pathways in schizophrenia. Genome-wide association studies have identified many areas of the genome linked to the genetic risk for schizophrenia. Using systems biology techniques, the first study identified the biological processes and/or anatomical locations that are overrepresented in the gene set and likely responsible for the common risk variant associated with schizophrenia. The research team found that many of these genes were associated with the synapse, including pre- and post-synaptic locations and multiple other synaptic components. These findings suggest that synaptic biology may help better understand genetic risk for schizophrenia. The second study examined at common variants that account for small amounts of risk and rare coding variants that account for large amounts of risk for schizophrenia. The researchers identified 10 rare coding variants that met very stringent criteria for association to schizophrenia and approximately 20 genes that did not meet stringent criteria but that were likely associated with schizophrenia. Dr. Gordon emphasized that several of these variants represent genes that are expressed in synapses.
Dr. Gordon then reviewed a study on the biology of anxiety and its intersection with the autonomic nervous system. One theory of anxiety is that it is a result of autonomic hypersensitivity. The ventromedial prefrontal cortex plays a part in the regulation of autonomic sensitivity; therefore, measuring its response to stimulation with adrenergic activity could show differences in the brains of individuals with and without generalized anxiety disorder. The researchers found that individuals with generalized anxiety disorder show a blunted response to adrenergic stimulation in their ventromedial prefrontal cortex. The upregulation of activity in this area of the brain may reduce anxiety in individuals who have this blunted response and/or further inform the theoretical underpinnings of autonomic sensitivity related to anxiety.
Finally, Dr. Gordon reviewed two treatment studies. First, he reviewed a study in which an intervention program called STEP, a specialty first-episode psychosis service, reduced the duration of untreated psychosis as compared to usual detection and referral efforts. In another treatment study, researchers investigated whether exposure response prevention treatment was more effective than medication for obsessive-compulsive disorder. Among participants who received exposure response prevention treatment, one group was tapered off their medication and another group continued their medication as usual. The researchers found mixed results. Both groups showed a gradual increase in symptom scores over the course of the 24-week study. However, those who continued their medication maintained slightly better scores for quality of life, enjoyment, satisfaction, and depression. Therefore, the study suggests that medication may continue to play a role in the maintenance of wellness even after exposure response prevention treatment.
DiscussionFollowing Dr. Gordon’s remarks, Council members inquired about perceived decreases in fundamental and disease-related basic research funding allocations, future studies in the synaptic biology of specific disorders, and how NIMH’s collaborations with other agencies can support the President’s Unity Agenda, and the potential implications for implementation science. Additionally, Council members requested further information about the omission of mental health in the ARPA-H announcement and NIMH’s evaluation plans for DEIA efforts.
- President’s State of the Union and Unity Agenda
- Stress-Related Psychopathology in Children and Adolescents during the COVID-19 Pandemic: Mechanisms of Risk and Resilience, Katie A. McLaughlin, Ph.D., Harvard University (NIH Videocast @1:19:11)
Dr. McLaughlin reviewed research on mental health during the COVID-19 pandemic. Dr. McLaughlin presented on the stressors that contributed to increases in mental health issues during the pandemic. She reviewed three models focused on the environmental aspect of stress as it relates to risk for psychopathology. Cumulative risk models emerged from developmental psychology and show how children’s experiences of multiple types of stress or adversity have an additive effect that increases their risk for psychopathology. Consistent with this model, evidence from the COVID-19 pandemic show that youths who experience a higher number of pandemic-related stressors are more likely to experience increases in internalizing and externalizing psychopathology during the pandemic. The second model focuses on how specific stressors—likely loss, threat, or rejection—might contribute to psychopathology. During the COVID-19 pandemic, stressors involving loss and chronic disruptions to daily life have had the strongest links with psychopathology. The third model is stress sensitization, which suggests that the link between stress and psychopathology is magnified among people with a history of early life adversity. Dr. McLaughlin reviewed evidence that children who have experienced repeated or severe trauma prior to the pandemic were more likely to develop psychopathology during the pandemic than children without a history of adversity.
Finally, Dr. McLaughlin discussed the clinical implications of these findings, focusing on digital interventions that could be scaled because of access to mental health services. Dr. Mclaughlin described three stress pathway models: stress appraisal, stress buffers, and stress mechanisms. The stress appraisal model focuses on how the interpretation and appraisal of a stressful event shape the response to the stressor. Cognitive reappraisal is an ongoing process of determining how a stressful situation is perceived that can modulate physical and mental responses. A study of stress and anxiety in adults during the pandemic showed that those who routinely engaged in cognitive reappraisal were less likely to experience symptoms of anxiety.
The stress buffer model suggests that protective factors can buffer against the emergence of psychopathology following stress and adversity. Studies of children and adolescents during the pandemic showed that protective factors, such as social support, low screen time, and structured daily routines, helped prevent the onset of psychopathology even in those experiencing high levels of pandemic-related stressors.
The stress mechanisms model describes how stress leads to changes to mechanisms that in turn predict the emergence of psychopathology symptoms. Dr. McLaughlin described potential mechanisms related to the pandemic. Her lab found that children with a higher number of pandemic-related stressors were more likely to have increased rumination, a maladaptive emotion regulation strategy, which in turn contributed to higher levels of internalizing symptoms following pandemic-related stressors. Another pandemic study found that a day with higher levels of diverse and novel experiences resulted in increased positive affect as compared to a day with low levels of diversity and novelty. A potential mechanism to explore is the stress related to fear of COVID-19 and other changes in the context of eased pandemic restrictions. Dr. McLaughlin reviewed a pilot imaging study looking at within-person changes in brain function as a stress mechanism. Exposure to an environmental threat (i.e., fearful faces) resulted in decreased activity in frontoparietal regions and increased activity in multiple regions of the default mode network. This within-person pattern of increased activity in the default mode network may suggest an increase in self-referential thinking such as rumination. Activity in these regions predicted increased symptoms of anxiety and depression in the following month.
Dr. McLaughlin ended by discussing the clinical implications of these findings. She focused on digital interventions that could be scaled given the limited access to in-person mental health services during the pandemic. She noted that racial/ethnic disparities in access to mental health services became even more pronounced. Environmental stress models highlight those who may be in most need of interventions, such as healthcare workers, families with financial adversity, children experiencing ongoing social isolation or early-life trauma, and those who experience increased discrimination and unfair treatment. Stress pathway models indicate that digital interventions to target stress appraisal/reappraisal; increase stress buffers (e.g., physical activity, decreased screentime); and provide self-guided, single-session interventions that target key stress mechanisms may be promising areas to explore.
DiscussionFollowing her talk, Dr. McLaughlin took questions from Council Members. Questions were posed about the age range of the study group and the considerations regarding the physical and social environment. In addition, there was discussion about disparities in access to care and potential recommendations for engaging hard to reach populations.
- High Dimensional Datasets in Genomics (NIH Videocast @2:08:59)
Dr. Gordon called for the establishment of a new Council workgroup focused on high-dimensional datasets. He indicated that there has been a dramatic increase in basic and applied research on high-dimensional phenotypes in recent years. This research typically seeks to examine pathological processes underlying mental illness and/or to identify markers of diagnostic, prognostic, or therapeutic value. Given the complexity and size of these datasets and the relative novelty of statistical and machine learning approaches used to analyze them, there are concerns about the rigor and reproducibility of the studies that use high-dimensional datasets.
He discussed the need for NIMH to define priorities and approaches to ensure rigor and reproducibility, as well as fiscal responsibility in this area. There is also a need to develop a standardized framework for experimental design and statistical inference and a conceptual framework for understanding the relationship between molecular, neural, and behavioral variation.
Therefore, the NIMH is seeking advisory Council member input through an ad hoc Council workgroup on high dimensional datasets. The purpose of this workgroup is to develop recommendations on appropriate conceptual frameworks and experimental and analytic designs for the use of high-dimensional datasets. The potential charge of this workgroup would be to address 1) statistical rigor and enhancing reproducibility, 2) the role of hypotheses and conceptual frameworks, 3) studies involving peripheral biomarkers, and 4) studies of potential clinical utility. NIMH is aiming to initiate a series of virtual meetings to develop a framework of recommendations to be presented at the May 2023 Council meeting.
Following the presentation, Dr. Gordon and Council members discussed the proposed workgroup. Council members asked for clarification about the focus and scope of the workgroup and encouraged NIMH to highlight hypothesis-driven studies. Members also asked for clarification regarding this workgroup’s relation to the NIMH Council Workgroup on Genomics, how the workgroup would address variations in technology and clinical data, and the need to highlight within-subject design studies.
- Concept Clearances (NIH Videocast @2:39:50)
-
Understanding Social Media and Youth Mental Health, Julia Zehr, Ph.D. (NIH Videocast @2:40:55)
Dr. Zehr presented a concept on the role of social media behaviors in youth mental health. The goal of the concept is to determine whether social media can be used as a tool to identify children at risk for psychopathology, characterize the role of digital social interactions in youth social development, and gather information on the methodological considerations for research on social media behaviors.
DiscussionDiscussants: Marguerita Lightfoot, Ph.D., Joel Nigg, Ph.D.
Both discussants supported the concept. Dr. Lightfoot suggested that methodologies to consider the bigger picture of social media (i.e., who uses different platforms and why, how social media is used, etc.) are important because social media platforms are constantly evolving.
Dr. Nigg agreed that there has been a rapid evolution of socialization over the last 30 years and that there is a need to be nimble and continually update methods. He added that recent meta-analyses have established a correlation between social media and mental health issues but not causality.
Patricia Recupero, M.D., J.D., commented that NIMH might consider ethical considerations, such as informed consent and data protection.
- Schizophrenia and Related Disorders during Mid- to Late-Life, Laura Rowland, Ph.D. (NIH Videocast @2:52:14)
Dr. Rowland presented a concept to advance translational research in schizophrenia and related psychotic disorders in mid- to late life with the hope of accelerating the development of prevention and intervention efforts. The concept aligns with NIMH Strategic Plan Goal 2 to examine mental illness trajectories across the lifespan and aims to examine understudied groups within this clinical population, including women and minoritized groups
DiscussionDiscussants: Sophia Vinogradov, M.D., Amy Kilbourne, Ph.D., M.P.H.
Both discussants were in support of the concept. Dr. Vinogradov suggested that greater insight into the unique mechanisms occurring in people with late-life onset of psychosis will likely yield novel ways of thinking about the traditional developmental trajectory of psychosis. The concept may also create opportunities to probe into the relationship between the psychosis spectrum and brain aging. Dr. Kilbourne expressed interest in mechanisms related to social determinants, and expressed the need to understand the mechanisms of what is happening to people in that nursing home settings, as well as any experience across the lifespan, such as homelessness or institutionalization.
Dr. Recupero asked how investigators would identify and recruit people not already engaged in treatment. Dr. Vinogradov suggested that online research projects can capture individuals who have not engaged in traditional medical treatment settings.
Marjorie Baldwin, Ph.D., encouraged including people who were diagnosed with schizophrenia at an early age who are doing well in their mid- to late life. There may be lessons to learn about the factors that contribute to success.
- Developing Quality Measures to Advance Mental Health Care Outcomes and Access, Jennifer Humensky, Ph.D., and Leonardo Cubillos, M.D., M.P.H. (NIH Videocast @3:02:52)
Dr. Humensky presented a joint concept led by the DSIR and the Center for Global Mental Health Research. The concept aims to support the development, testing, validation, and implementation of mental health quality measures to advance mental health care access, outcomes, and quality across the United States and other low-, middle-, and high -income countries.
DiscussionDiscussants: Marjorie Baldwin, Ph.D., Joseph Telfair, Dr.P.H, M.P.H.
Both discussants were in support of the concept. Dr. Baldwin suggested that, while clinical measures were necessary, they are not necessarily sufficient for measuring the complexity of mental health. She suggested including a broad range of outcome measures such as quality of life, meaningful recovery, and community engagement.
Dr. Telfair commented that the concept is broad and that it will be important to identify measures within context, define the measure operationally, and determine the level of cost measure will have across different populations. There is also a need to establish criteria for development and implementation for investigators
Dr. Recupero said that access to smartphones is widespread even in lower-income countries and that there might be an emphasis on using smartphones to monitor and measure outcomes.
- Suicide Prevention Across the Lifespan in Low- and Middle-Income Countries, Andrea Horvath Marques, M.D., Ph.D. (NIH Videocast @3:16:20)
Dr. Horvath Marques presented a concept on global research to implement and evaluate scalable and financially sustainable preventive interventions and strategies to reduce suicide risk and promote resilience. The concept also aims to support research to implement and evaluate surveillance systems and to implement systems- and policy-level strategies to influence the uptake, scaling, and sustainability of prevention approaches.
DiscussionDiscussants: Matthew Nock, Ph.D., Marguerita Lightfoot, Ph.D.
Both discussants were in support of this concept. Dr. Nock said that the concept addressed important gaps in knowledge. Specifically, there is a need to improve studies in suicide risk prediction and prevention of suicide behaviors and death through scalable, efficient interventions that could be deployed for a range of outcomes. There is a lot that can be learned from low- and middle-income countries that could be implemented in high-income countries.
Dr. Lightfoot acknowledged the staggering challenge of suicide in low- and middle-income countries. She reiterated the importance of implementation science and scalability to avoid replicating some of the limitations from past studies in the United States. She added that, in the effort to implement culturally adapted interventions, it will be important to avoid a colonial approach using western knowledge to dictate what works or not. She also was encouraged that this concept included social determinants of health and other risk factors, such as stigma and discrimination.
- Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (Reissue), Gregory Greenwood, Ph.D., M.P.H. (NIH Videocast @3:26:35)
Dr. Greenwood presented a concept on innovative behavioral and social science research to optimize HIV prevention and care. This concept will encourage research on community-centered, multidisciplinary, multisectoral, and multilevel approaches to address the complex psychosocial factors associated with prevention, intervention uptake and adherence, and communication strategies to reduce disparities.
DiscussionDiscussants: Joseph Telfair, Dr.P.H., M.P.H., Pamela Collins, M.D., M.P.H.
Both discussants were in support of this concept. Dr. Telfair recommended focusing on implementation challenges in prevention approaches.
Dr. Collins suggested developing specific guidance toward the types of science they want to fund. For instance, it may be important to emphasize broader implementation of evidence-based preventive interventions or structural interventions. She asked if there were opportunities for natural experiments in settings where there has been policy reform, such as the decriminalization of behaviors.
Dr. Recupero suggested that the idea that HIV creates a brain disorder early in the infective process and how it impacts the care continuum outcomes could be further emphasized.
-
- Adjournment
Dr. Gordon invited Council members to submit any additional comments or questions regarding the concept clearances. The open session of the meeting adjourned at 4:45 pm.
CLOSED PORTION OF THE MEETING
The grant application review portion of the meeting was closed to the public in accordance with provisions as set forth in Section 552b(c)(4) and 552b(c)6. Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended.Tracy Waldeck, Ph.D., Executive Secretary of the Council, explained policies and procedures regarding confidentiality and avoidance of conflict-of-interest to the members of the Council.
Members absented themselves from the meeting during the discussion of and voting on applications from their own institutions, or other applications in which there was a potential conflict of interest, real or apparent. Members were asked to sign a statement to this effect.
- Review of Applications
Refer to Appendix A. - Adjournment
Dr. Gordon thanked the Council members. The closed session of the NAMHC meeting adjourned at approximately 4:45 p.m. on June 7, 2022.
VII. Review of Applications
Refer to Appendix A.
VIII. Adjournment
Dr. Gordon thanked the Council members. The closed session of the NAMHC meeting adjourned at approximately 4:45 p.m. on June 7, 2022.
| DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH NATIONAL INSTITUTE OF MENTAL HEALTH NATIONAL ADVISORY MENTAL HEALTH COUNCIL |
|
| CHAIRPERSON Joshua A. Gordon, M.D., Ph.D. Director National Institute of Mental Health Bethesda, MD |
EXECUTIVE SECRETARY Tracy Waldeck, Ph.D. Director Division of Extramural Activities National Institute of Mental Health Bethesda, MD |
| Members | |
| Edwin G. Abel, III, Ph.D. (24) Chair and Departmental Executive Officer Department of Neuroscience and Pharmacology Carver College of Medicine University of Iowa Iowa City, IA |
Matthew K. Nock, Ph.D. (24) Edgar Pierce Professor of Psychology Harvard College Professor Chair, Department of Psychology Harvard University Cambridge, MA |
| Laura A. Almasy, Ph.D. (22) Professor Department of Genetics Perelman School of Medicine University of Pennsylvania Philadelphia, PA |
Patricia R. Recupero, M.D., J.D. (24) Senior Vice President of Education and Training Care New England Butler Hospital Providence, RI |
| Marjorie L. Baldwin, Ph.D. (22) Professor Department of Economics W.P. Carey School of Business Arizona State University Tempe, AZ |
Bryan L. Roth, M.D., Ph.D. (24) Michael Hooker Distinguished Professor Department of Pharmacology School of Medicine University of North Carolina at Chapel Hill Chapel Hill, NC |
| Pamela Y. Collins, M.D., M.P.H, (24) Professor of Psychiatry and Behavioral Sciences Professor of Global Health Schools of Medicine and Public Health University of Washington Seattle, WA |
Joseph Telfair, Dr.P.H, M.P.H (23) Professor and Associate Dean for Public Health Practice and Research Karl E. Peace Distinguished Chair of Public Health Fellow, Royal Society of Public Health Jiann-Ping Hsu College of Public Health Georgia Southern University Statesboro, GA |
| David Goldstein, Ph.D. (23) Director Institute for Genetic Medicine Columbia University Hammer Building New York, NY |
Sophia Vinogradov, M.D. (22) Donald W. Hastings Endowed Chair University of Minnesota Medical School Professor and Department Head Department of Psychiatry Minneapolis, MN |
| Kamilah Jackson, M.D. (23) Medical Director PerformCare Robbinsville, NJ |
Hongkui Zeng, Ph.D. (23) Executive Vice President and Director Allen Institute for Brain Science Seattle, WA |
| Marguerita A. Lightfoot, Ph.D. (24) Professor Associate Dean for Research OHSU-PSU School of Public Health Portland, OR |
Joel T. Nigg, Ph.D. (24) Professor and Vice Chair for Psychology Director, Center for ADHD Research Department of Psychiatry Oregon Health and Science University Portland, OR |
EX OFFICIO MEMBERS
Office of the Secretary, DHHS
Xavier Becerra, J.D.
Secretary
Department of Health and Human Services
Washington, DC
National Institutes of Health
Lawrence A. Tabak, D.D.S., Ph.D.
Acting Director
National Institutes of Health
Bethesda, MD
Department of Veterans Affairs
Amy M. Kilbourne, Ph.D., M.P.H.
Director, Quality Enhancement Research Initiative (QUERI)
U.S. Department of Veterans Affairs
Professor of Learning Health Sciences
University of Michigan Medical School
Ann Arbor, MI
Department of Defense
Liaison Representative
Anita Everett, M.D., DFAPA.
Director
Center for Mental Health Services
US, HHS Substance Abuse and Mental Health Services
Rockville, MD
Others Present
Staff Present Virtually for Open Session
|
Susannah Allison |
Rebecca Garcia |
Jenni Pacheco |
Other Non-Federal Members Present Virtually:
Debra Gilliam, Transcriber
Marie Rowland, Science Writer
Candice Martin, Captioner
Staff Present Virtually for Closed Session
|
Lisa Alberts |
Miri Gitik |
Michele Pearson |
Appendix A
Summary of Primary National Institute of Mental Health Applications Reviewed Council: May 2022
| IRG Recommendation | ||||||||
|---|---|---|---|---|---|---|---|---|
| Category | Scored # | Scored Direct Cost $ | Not Scored (NRFC) # | Not Scored (NRFC) Direct Cost $ | Other # | Other Direct Cost $ | Total # | Total Direct Cost $ |
| Research | 641 | $1,648,498,913 | 493 | $710,248,154 | 1 | 1135 | $2,358,747,067 | |
| Research Training | 0 | 0 | 0 | 0 | ||||
| Career | 89 | $75,287,429 | 28 | $22,385,734 | 0 | 117 | $97,673,163 | |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Totals | 730 | $1,723,786,342 | 521 | $732,633,888 | 1 | $0 | 1252 | $2,456,420,230 |
Appendix B
Public Comments
National Advisory Mental Health Council – Spring 2022 Session
- A. Griffen - Maternal Mental Health Leadership Alliance
- M. Heidaran - Cory Heidaran Charitable Foundation